Sticking To Nitrosamine Evaluations Deadline Is Priority For EU Regulators
Industry's Request For A Standardized Approach Has Been Set Aside
Executive Summary
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
You may also be interested in...
Europe Stands Firm On Nitrosamine Assessment Deadline For APIs
The European Directorate for the Quality of Medicines & HealthCare says it will not extend the deadline for nitrosamine-related risk assessment of active substances even though an extension is in place for assessments of finished products.
Companies Get Yet More Time To Assess Nitrosamine Risk In EU
After EU regulators decided that biological medicines should be reviewed for the presence of possible nitrosamine impurities – as is already required for chemical medicines – new deadlines have been agreed on to give companies enough time to comply.
More Time For EU Nitrosamine Evaluations Due To COVID-19
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.